IMU 5.56% 5.7¢ imugene limited

Ann: Imugene Licenses Allogeneic CD19 CAR T Cell Therapy, page-85

  1. 271 Posts.
    lightbulb Created with Sketch. 400
    So is this it in a nut shell:

    - we have bought a CAR-T for $12m
    - That CAR-T has been greenlighted to go straight to a registrational trial
    - Because of its orphan status that trial is way quicker and easier
    - The trial will cost $20m

    If I am correct in my understanding then those are all the good things about this deal. Indeed, it seems a good deal period. The bad aspect is the CAP Raise. Totally unnecessary and certainly should not have been done at a discount. Could have been funded from existing cash.

    I don't agree that we should have bought this company given they hold other tech we don't need and the license price was about as cheap as it gets. I would hope there is still more announcements to come before we trade again. I hope they just consolidate now and dual list on the nasdaq to get it over with. I think that would help lift the SP.
 
watchlist Created with Sketch. Add IMU (ASX) to my watchlist
(20min delay)
Last
5.7¢
Change
0.003(5.56%)
Mkt cap ! $417.2M
Open High Low Value Volume
5.5¢ 5.8¢ 5.2¢ $2.499M 45.00M

Buyers (Bids)

No. Vol. Price($)
2 1921794 5.6¢
 

Sellers (Offers)

Price($) Vol. No.
5.7¢ 1368288 7
View Market Depth
Last trade - 16.10pm 28/06/2024 (20 minute delay) ?
IMU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.